Cargando…
Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR‐T cell infusion
KEY CLINICAL MESSAGE: The prognosis of patients with relapsed or refractory (R/R) BL is poor with limited response to salvage therapy, especially for patients with early relapse (<6 months) or refractory disease. Novel therapies may be promising but need refinement. ABSTRACT: The prognosis of pat...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227197/ https://www.ncbi.nlm.nih.gov/pubmed/37260617 http://dx.doi.org/10.1002/ccr3.7361 |